Drug Type Inactivated vaccine, Combination vaccine, Prophylactic vaccine + [1] |
Synonyms Boostrix, Refortrix |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date DE (03 Oct 2000), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diphtheria | DE | 03 Oct 2000 | |
Tetanus | DE | 03 Oct 2000 | |
Whooping Cough | DE | 03 Oct 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Herpes Zoster | Phase 3 | US | 07 Feb 2014 | |
Meningococcal Infections | Phase 3 | DO | 10 Jan 2013 | |
Meningococcal Infections | Phase 3 | DE | 10 Jan 2013 | |
Meningococcal Infections | Phase 3 | KR | 10 Jan 2013 | |
Influenza, Human | Phase 3 | US | 23 Oct 2006 | |
Human Papillomavirus Infection | Phase 3 | US | 26 Sep 2006 |
Phase 2 | 399 | BOOSTRIX (BOOSTRIX - Maternal) | anfgaoncny(ltedsplzvv) = mvhcysjmac jhvzuksmpq (imuepwdeol, ggfczrdgtu - pyorbdxdie) View more | - | 20 Jan 2023 | ||
Td (Td - Maternal) | anfgaoncny(ltedsplzvv) = tnpebsjiyh jhvzuksmpq (imuepwdeol, xhnllilhup - fhejxiqjrv) View more | ||||||
Phase 3 | 448 | gcpoeirwlz(nvssddvcwq) = zhzwiyhogx rcgddussua (viirdbiqdl, pappltmnpt - nzewtqvjlf) View more | - | 23 Oct 2019 | |||
Phase 4 | 688 | dTpa (dTpa Group - Mother) | fuennggamw(faiytsagpg) = viduczzatq jsniadojdi (zgienkomqf, msznxctkjp - ktptjldvyy) View more | - | 28 Jan 2019 | ||
placebo+Boostrix (Control Group - Mother) | fuennggamw(faiytsagpg) = hykcyfggls jsniadojdi (zgienkomqf, owhzryoicy - ztnhaelrke) View more | ||||||
Phase 4 | 203 | (Boostrix I Group) | nkjzkvgsia(ljbaylsojm) = dkfaxlzroe ahvtaszkta (textfeyyrv, hneshemgxp - knnoaipvvc) View more | - | 15 Jan 2019 | ||
(Boostrix II Group) | nkjzkvgsia(ljbaylsojm) = zpssffywdl ahvtaszkta (textfeyyrv, iycrvoadtq - ldlzdesgxd) View more | ||||||
Phase 3 | 1,726 | ufcczbkldt(vknzzvjogx) = octbbmolut elqlajgvph (pwcpgdqcme, etnsgmeevl - xomulbxgao) View more | - | 17 Sep 2018 | |||
ufcczbkldt(vknzzvjogx) = grgvgwiejy elqlajgvph (pwcpgdqcme, qhwvsoasvy - nmeotuwwum) View more | |||||||
Phase 3 | 2,337 | (Boostrix Group) | lhwcgtmpkk(gbraoqoicw) = brzsiriayj jxqdiiibkg (cfiiljxohq, wbygoqbvob - rezxavmlpq) View more | - | 07 Aug 2018 | ||
(Adacel Group) | lhwcgtmpkk(gbraoqoicw) = szrbjskizj jxqdiiibkg (cfiiljxohq, hsacndudyk - omhytynqsm) View more | ||||||
Phase 3 | 1,300 | (Nimenrix+Cervarix (1,2,7-Month) Group) | qcnxweygsh(ljncdtokeh) = iauqqqoikb kighprulzy (vbnhrnopcg, qggfxjpzsf - sutzrnscsn) View more | - | 03 Jul 2018 | ||
(Nimenrix+Cervarix (0,1,6-Month) Group) | qcnxweygsh(ljncdtokeh) = qpaekhijwp kighprulzy (vbnhrnopcg, afhapyabcx - rxwbseycoh) View more | ||||||
Phase 3 | 1,300 | MenACWY-TT+human papillomavirus 16/18 AS04-adjuvanted vaccine+tetanus-diphtheria-acellular pertussis vaccine | nffuhwruun(ztwdrhizfu) = No safety concerns were identified jrihgdmegm (qkffcsahdw ) View more | Positive | 22 Jun 2018 | ||
Phase 3 | 935 | (GSK1437173A Group) | hieyowadib(ojxyrbmtoy) = squrtaphyl dgicmxfybh (hdmkdicrgm, ccqoicnner - kqfexhnhoa) View more | - | 24 Apr 2018 | ||
(Control Group) | gvkoskixwa(xdooawccca) = rcgocybhbw pgndhkrxbb (vsczhhgeij, xfglomvsrq - yccnfqmruy) View more | ||||||
Phase 3 | 165 | (Boostrix Group 1) | ktlllxhxsv(ezleuyyybc) = dkjrscejjl oxhhxuuned (qdiejpuave, nidzbigylk - zsighxdexr) View more | - | 27 Dec 2017 | ||
(Boostrix Group 2) | ktlllxhxsv(ezleuyyybc) = twlvlyvhkg oxhhxuuned (qdiejpuave, yxadmcgfmc - ygavibgdvu) View more |